# Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Source: https://onco.cc/trials/nct04935229/  
OnCo record `nct04935229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Nelitolimod run by TriSalus Life Sciences, Inc., terminated.

## Summary

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma is a phase 1 interventional study registered as NCT04935229 by TriSalus Life Sciences, Inc., with 67 participants enrolled, started 2021-08-02, primary completion reached 2024-07-17. Conditions recorded: Metastatic Uveal Melanoma in the Liver. Interventions recorded: SD-101, Nivolumab, Ipilimumab, Nivolumab and Relatlimab. Reason given for stopping: The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04935229
- Phase: 1
- Setting: A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
- Sponsor: TriSalus Life Sciences, Inc.
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT04935229: https://clinicaltrials.gov/study/NCT04935229

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Nelitolimod](https://onco.cc/drugs/nelitolimod/)
- companies: [TriSalus Life Sciences](https://onco.cc/companies/trisalus-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct04935229.json